New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
10:08 EDTIMMUImmunomedics provides update on subcutaneous injections of Veltuzumab
Immunomedics announced that subcutaneous administration of veltuzumab, as a single agent, demonstrated promising activity in patients with relapsed immune thrombocytopenia, even in more heavily treated patients with the chronic disease, and in patients with chronic lymphocytic leukemia. In a published study, veltuzumab reversed life threatening anemia and thrombocytopenia in a patient with systemic lupus erythematosus who was unresponsive to rituximab. In non-Hodgkin lymphoma patients who had received prior therapies, 4 once-weekly infusions of veltuzumab produced a complete response rate of 25% in a study of 84 patients, even at the low dose of 80 mg/m2 given intravenously.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
12:33 EDTIMMUImmunomedics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
09:32 EDTIMMUImmunomedics granted breakthrough therapy designation for sacituzumab govitecan
Immunomedics announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease.
09:29 EDTIMMUImmunomedics granted Breakthrough Therapy Designation from FDA for IMMU-132
Subscribe for More Information
February 3, 2016
16:05 EDTIMMUImmunomedics sees Phase 3 PANCRIT-1 trial completing enrollment in 2016
Subscribe for More Information
16:03 EDTIMMUImmunomedics reports Q2 EPS (15c), two estimates (14c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use